Immunogenicity and Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds.
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary)
- Indications Measles; Mumps; Rubella; Varicella zoster virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 23 Dec 2010 Actual end date changed from Mar 2010 to Dec 2010 as reported by ClinicalTrials.gov.
- 23 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.